Verix Health said today that it closed a Series A round worth $8 million for the steerable devices it’s developing.
Santa Clara, Calif.-based Verix said Ajax Health led the round, which included Aperture Venture Partners and Western Technology Investment. The funds are earmarked for R&D and preparations for commercialization for the steerable devices, which are designed to treat solid-organ cancers.
“From the beginning, our vision has been to create a platform capable of enabling advanced diagnosis and therapy for a spectrum of diseases,” CEO Sasha Schrode said in prepared remarks. “We are honored to have the support of Ajax Health, Aperture and WTI to help us achieve our important mission. Through this collaboration, we believe we are making significant progress toward innovating devices that will have a profound impact on patients.”
“Verix Health is positioned to address a critical unmet need—navigation of complex anatomies to enable diagnostic and therapeutic interventions in oncology,” added Ajax Health chairman & CEO Duke Rohlen. “We are excited to join the team and help the company realize its potential for patient benefit and value creation.”
A slate of Ajax Health executives are joining Verix, with Rohlen as chairman, Doug Koo as CFO and Joe Koblish as CTO, according to a press release.
